CHRS:NASDAQ, Coherus BioSciences, Inc.

Why CHRS stock fell on November 18

Coherus BioSciences, Inc. fell 14.4% on Wednesday, November 18, 2026, on 2,553,500 shares. The headline around the move:

CHRS stock overview

Coherus BioSciences, Inc. (CHRS:NASDAQ) closed at $0.370 on November 20, 2026, down 4.47% on the day. The stock trades 85.9% below its 52-week high of $2.62 and 1.9% above its 52-week low of $0.363. Over the past year, it lost 68.1%. Coherus BioSciences, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).

Key figures

Price
$0.370
Day change
-4.47%
Volume
2,521,616
Average volume
1,782,165
Market cap
57M+
52-week range
$0.363 – $2.62
50-day average
$0.986
200-day average
$1.43

Price action over the past year

In 252 trading sessions since November 20, 2025, CHRS closed higher on 116 days (46%). Its best day was January 23, 2026 (+29.56%) and its worst was October 29, 2026 (-22.59%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 2 times.

Recent signals

CHRS news

About Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company's product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonsmall cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, Behcet's Disease, Crohn's Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of...

Similar stocks

Find more stocks like CHRS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.